We have recently updated our Privacy Policy to include information regarding the cookies we collect. By continuing to use this website you agree to our Privacy Policy and Terms of Use.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 20, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 8, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 24, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will
Announcing Positive Phase 3 Results for Zuranolone, an Investigational Two-Week, Once Daily Therapeutic Being Evaluated for Major Depressive Disorder Webcast scheduled for 8:00a.m. ET on Tuesday, June 15 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 15, 2021-- Sage Therapeutics (Nasdaq: SAGE), a
At the Day 15 primary endpoint, zuranolone 50 mg showed a statistically significant and clinically meaningful reduction in depressive symptoms as measured by HAMD-17 (p=0.0141) compared to placebo Rapid onset of treatment effect was seen in HAMD-17 results at Days 3, 8, and 12 Patients with a
Creating a movement from the inside out – to break the stigma of mental health conditions and empower employees to be champions of brain health Learn more at www.MentalHealthActionDay.org CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 20, 2021-- Sage Therapeutics (Nasdaq:SAGE), a biopharmaceutical company
Debut webcast to provide deep dive on SAGE-718, the company’s lead neuropsychiatry product candidate being studied for cognitive disorders associated with NMDA receptor dysfunction, including Huntington’s, Parkinson’s, and Alzheimer’s diseases Webcast scheduled for 8:30 a.m.
Company on-track to initiate placebo-controlled Phase 2 trial with SAGE-718 in Huntington’s disease in late 2021, as the target for the first indication for SAGE-718, following encouraging signals in Phase 1 data PARADIGM Study with SAGE-718 showed improved performance from baseline on multiple
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 28, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 20, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast
